Ardelyx, Inc. ARDX
3.03 USD 0.00 (+0.00%)
At closeNov 3, 2026, 7:42 PM EST
3.27 +0.24 +7.92%
After hours · Nov 3, 7:42 PM ET
3.02 Day range 3.10
2.96 52-week range 8.40
- YTD
- -48.03%
- 1 year
- -48.82%
- Market cap
- 782.31M
- Revenue (ttm)
- 450.89M
- Profit margin
- -12.35%
- EPS (ttm)
- -0.23
- Shares out
- 258.19M
- Forward P/E
- 15.44
- YTD return
- -48.03%
- 1-year return
- -48.82%
- Volume
- 6.12M
- Avg volume
- 4.61M
- Open
- 3.06
- Previous close
- 3.03
- Day's range
- 3.02 – 3.10
- 52-week range
- 2.96 – 8.40
- Beta
- 0.73
- Analysts
- Strong Buy
- Price target
- 12.90 (+325.7%)
- Earnings date
- Oct 29, 2026
2Y -2.86 (-48.56%)
Key statistics
- Enterprise value
- 972.51M
- PEG ratio
- 0.00
- Price / sales
- 2.23
- Price / book
- 6.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.80%
- Free cash flow
- 20.47M
- Total cash
- 281.83M
- Total debt
- 282.51M
- Return on equity
- -38.61%
- Short % of float
- 10.76%
- 50-day average
- 5.09
- 200-day average
- 5.97
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 12.90 +325.7% upside
Now 3.03
- Target (low)
- 8.00
- Target (mean)
- 12.90
- Target (high)
- 18.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate -0.01863.
Financials — quick view
ARDX Revenue — quarterly 120.88M
ARDX Net income — quarterly -16.72M
ARDX EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.03 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.06545 | -0.07 | 0.00 | -6.95% |
| Apr 30, 2026 | Mar 31, 2026 | -0.13 | -0.15 | -0.02 | -15.38% |
| Feb 19, 2026 | Dec 31, 2025 | 0.02 | 0.02 | 0.00 | 0.00% |
| Oct 30, 2025 | Sep 30, 2025 | -0.06 | -0.00401 | +0.06 | +93.32% |
| Aug 4, 2025 | Jun 30, 2025 | -0.13 | -0.08 | +0.05 | +38.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 18, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 10, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | BTIG | main | Buy | Buy |
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ardelyx.com
News
Ardelyx, Inc. (ARDX) Q3 2026 Earnings Call Transcript 
ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX 
What Ardelyx (ARDX) Said on Its Q3 Earnings Call 
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates 
Ardelyx (ARDX) Reports Break-Even Earnings for Q3 
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX 
Ardelyx Q3 2026 Earnings Call Transcript 
Ardelyx Q3 Sales $125.500M Miss $128.420M Estimate 
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update 
ARDELYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Your note
Sign in to keep a note on ARDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERTRAND WILLIAM C JR | Director | Stock Award(Grant) | Jun 15, 2026 | 329,507 |
| BISHOP JOHN E | Officer | Sale | May 20, 2026 | 336,845 |
| FOSTER ERIC DUANE | Officer | Sale | May 20, 2026 | 417,972 |
| KELLIHER MICHAEL | Officer | Sale | May 20, 2026 | 357,418 |
| MOTT DAVID M | Director | Stock Award(Grant) | Jun 15, 2026 | 3,349,660 |
| RAAB MICHAEL G | Chief Executive Officer | Sale | Jul 14, 2026 | 1,703,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.43% | 23,504,630 | 91.43M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.50% | 16,202,700 | 63.03M | Jun 29, 2026 |
| Millennium Management Llc | 5.58% | 13,900,773 | 54.07M | Jun 29, 2026 |
| State Street Corporation | 5.36% | 13,356,128 | 51.96M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 10,471,494 | 40.73M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 3.83% | 9,546,732 | 37.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 7,404,867 | 28.80M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.97% | 7,389,361 | 28.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 6,400,256 | 24.90M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.51% | 6,265,909 | 24.37M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 2,702,696 | 10.51M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.96% | 2,392,375 | 9.31M | May 30, 2026 |